CN1451388A - 防治病毒引起非典型性肺炎等传染病的药物 - Google Patents

防治病毒引起非典型性肺炎等传染病的药物 Download PDF

Info

Publication number
CN1451388A
CN1451388A CN03131438A CN03131438A CN1451388A CN 1451388 A CN1451388 A CN 1451388A CN 03131438 A CN03131438 A CN 03131438A CN 03131438 A CN03131438 A CN 03131438A CN 1451388 A CN1451388 A CN 1451388A
Authority
CN
China
Prior art keywords
medicine
ribavirin
lecithin
phosphate buffer
infectious disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN03131438A
Other languages
English (en)
Inventor
蔡海德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1451388A publication Critical patent/CN1451388A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种防治病毒引起非典型性肺炎等传染病的药物，其成分为：利巴韦林、卵磷脂或豆磷脂、D－葡萄糖、乳糖、胆固醇、无水乙醇、磷酸盐缓冲液。该药物制备方法是：将卵磷脂或豆磷脂用乙醇溶解，加入磷酸盐缓冲液，进行减压蒸馏，置组织捣细机搅拌，经过灭菌处理后，加入利巴韦林、D－葡萄糖、乳糖、胆固醇，再加入经灭菌后的0.01ml/L磷酸盐缓冲液至总药液量为1000－2000ml，膜过滤，灌装后冷冻干燥，制成成品。本发明的优点是：将以利巴韦林为有效成分的药物制成脂质体，使药物主要在血液循环***、肝、脾、肺、骨髓等组织器官中蓄积，从而提高了药物的治疗指数，减少了药物的治疗剂量，大大降低药物的毒副作用。

Description

防治病毒引起非典型性肺炎等传染病的药物
技术领域
本发明涉及一种药物，特别是指一种用于预防和治疗病毒引起的严重呼吸***综合症(非典型性肺炎)、流感、甲型肝炎、肺炎、疱疹、麻疹等传染性疾病的药物。
背景技术
病毒引起的严重呼吸***综合症(非典型性肺炎)、流感、甲型肝炎、肺炎、疱疹、麻疹等传染性疾病，对人的健康危害性很大，甚至会危及人的生命，而且一些疾病具有传染性，对整个社会都会造成很大影响。已知利巴韦林单方制剂(普通制剂)对防治病毒性传染疾病能够起到一定的作用，但需使用较大剂量，而且在使用剂量大的情况下药物同时产生较强的毒副作用，如致畸、对心脏损害、对呼吸***可致患者呼吸困难，胸痛等。
发明内容
本发明的目的在于提供一种防治病毒引起非典型性肺炎等传染病的药物，以利巴韦林为有效成分，将其制成脂质体，使药物主要在血液循环***、肝、脾、肺和骨髓等组织器官中蓄积，提高药物的治疗指数，减少药物的治疗剂量，大大降低药物的毒副作用。
本发明的上述目的可以通过以下技术方案来实现。
一种防治病毒引起非典型性肺炎等传染病的药物，其成分及配比如下：
利巴韦林                     50-100克
卵磷脂或豆磷脂               利巴韦林摩尔数的8-10倍
D-葡萄糖                     20-30克
乳糖                         30-40克
胆固醇                       利巴韦林摩尔数的8-10倍
无水乙醇                     200-400ml
磷酸盐缓冲液(0.01mol/L       至总量为1000-2000ml
             PH值4.0-8.0)
本发明提供的药物经以下工艺制成：
1、将卵磷脂或豆磷脂用乙醇溶解，加入0.01ml/L磷酸盐缓冲液，混合均匀，进行减压蒸馏；
2、待乙醇挥发尽后，置组织捣细机搅拌5-15分钟，在115-125℃下蒸汽灭菌30分钟，用超声波超声搅拌两次，每次10分钟；
3、加入利巴韦林、D-葡萄糖、乳糖、胆固醇，至完全溶解后，再加入经灭菌后的0.01ml/L磷酸盐缓冲液至总药液量为1000-2000ml，用0.22μm的膜过滤；
4、灌装药液，并半加塞，送入冷冻干燥箱内，在-30-40℃和2-50Pa下冷冻干燥，使制品水分≤3％后，压塞，轧盖，成品检验合格，包装入库。
本发明提供的药物其优点是：将以利巴韦林为有效成分的药物制成脂质体，使药物主要在血液循环***、肝、脾、肺、骨髓等组织器官中蓄积，从而提高了药物的治疗指数，减少了药物的治疗剂量，大大降低药物的毒副作用。
具体实施方式
下面提供本发明的实施例。
实施例1：
一种防治病毒引起非典型性肺炎等传染病的药物，其成分及配比如下：
利巴韦林                     50克
卵磷脂或豆磷脂               利巴韦林摩尔数的8倍
D-葡萄糖                     20克
乳糖                         30克
胆固醇                       利巴韦林摩尔数的8倍
无水乙醇                     200ml
磷酸盐缓冲液(0.01mol/L      至总量为1000ml
             PH值4.5)
本药物的制备方法如下：
1、将卵磷脂或豆磷脂用乙醇溶解，加入适量0.01ml/L磷酸盐缓冲液，混合均匀，进行减压蒸馏；
2、待乙醇挥发尽后，置组织捣细机搅拌5-15分钟，在115-125℃下蒸汽灭菌30分钟，用超声波超声搅拌两次，每次10分钟；
3、加入利巴韦林、D-葡萄糖、乳糖、胆固醇，至完全溶解后，再加入经灭菌后的0.01ml/L磷酸盐缓冲液至总药液量为1000ml，用0.22μm的膜过滤；
4、用西林瓶灌装药液，分装成1000支，并半加塞，送入冷冻干燥箱内，在-30-40℃和2-50Pa下冷冻干燥，使制品水分≤3％后，压塞，轧盖，制成冻干针剂，成品检验合格，包装入库。
实施例2：
一种防治病毒引起非典型性肺炎等传染病的药物，其成分及配比如下：
利巴韦林                     100克
卵磷脂或豆磷脂               利巴韦林摩尔数的10倍
D-葡萄糖                     30克
乳糖                         40克
胆固醇                       利巴韦林摩尔数的10倍
无水乙醇                     400ml
磷酸盐缓冲液(0.01mol/L       至总量为2000ml
             PH值6.0-8.0)
本药物的制备方法如下：
1、将卵磷脂或豆磷脂用乙醇溶解，加入适量0.01ml/L磷酸盐缓冲液，混合均匀，进行减压蒸馏；
2、待乙醇挥发尽后，置组织捣细机搅拌5-15分钟，在115-125℃下蒸汽灭菌30分钟，用超声波超声搅拌两次，每次10分钟；
3、加入利巴韦林、D-葡萄糖、乳糖、胆固醇，至完全溶解后，再加入经灭菌后的0.01ml/L磷酸盐缓冲液至总药液量为2000ml，用0.22μm的膜过滤；
4、用西林瓶灌装药液，分装成1000支，并半加塞，送入冷冻干燥箱内，在-30-40℃和2-50Pa下冷冻干燥，使制品水分≤3％后，压塞，轧盖，制成冻干针剂，成品检验合格，包装入库。
本发明也可将冻干针剂按1支溶于含氮酮2-10％，10-20％的无水乙醇的无菌注射用水中，灌入喷雾器瓶中，制成喷雾剂。

Claims (3)

1、一种防治病毒引起非典型性肺炎等传染病的药物，其特征在于它的成分及配比如下：
利巴韦林                     50-100克
卵磷脂或豆磷脂               利巴韦林摩尔数的8-10倍
D-葡萄糖                     20-30克
乳糖                         30-40克
胆固醇                       利巴韦林摩尔数的8-10倍
无水乙醇                     200-400ml
磷酸盐缓冲液(0.01mol/L       至总量为1000-2000ml
            PH值4.0-8.0)
2、一种如权利要求1所述防治病毒引起非典型性肺炎等传染病的药物的制备方法，其特征在于经过以下工艺步骤：
(1)将卵磷脂或豆磷脂用乙醇溶解，加入0.01ml/L磷酸盐缓冲液，混合均匀，进行减压蒸馏；
(2)待乙醇挥发尽后，置组织捣细机搅拌5-15分钟，在115-125℃下蒸汽灭菌30分钟，用超声波超声搅拌两次，每次10分钟；
(3)加入利巴韦林、D-葡萄糖、乳糖、胆固醇，至完全溶解后，再加入经灭菌后的0.01ml/L磷酸盐缓冲液至总药液量为1000-2000ml，用0.22μm的膜过滤；
(4)用西林瓶灌装，分装成1000支，并半加塞，送入冷冻干燥箱内，在-30-40℃和2-50Pa下冷冻干燥，使制品水分≤3％后，压塞，轧盖，制成脂质体冻干针剂，成品检验合格，包装入库。
3、根据权利要求2所述的防治病毒引起非典型性肺炎等传染病的药物的制备方法，其特征在于：将步骤(4)制得的脂质体冻干针剂按每支溶于含氮酮2-10％，含无水乙醇10-20％，总体积20ml的无菌注射用水中，制成喷雾剂。
CN03131438A 2000-06-07 2003-05-16 防治病毒引起非典型性肺炎等传染病的药物 Pending CN1451388A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/015515 WO2001093683A1 (en) 2000-06-07 2000-06-07 Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin

Publications (1)

Publication Number Publication Date
CN1451388A true CN1451388A (zh) 2003-10-29

Family

ID=21741461

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2007101418683A Pending CN101108176A (zh) 2000-06-07 2000-06-07 用(r)-奥昔布宁和(r)-去乙基奥昔布宁治疗平滑肌机能亢进
CN00819623A Pending CN1454054A (zh) 2000-06-07 2000-06-07 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进
CN03131438A Pending CN1451388A (zh) 2000-06-07 2003-05-16 防治病毒引起非典型性肺炎等传染病的药物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNA2007101418683A Pending CN101108176A (zh) 2000-06-07 2000-06-07 用(r)-奥昔布宁和(r)-去乙基奥昔布宁治疗平滑肌机能亢进
CN00819623A Pending CN1454054A (zh) 2000-06-07 2000-06-07 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进

Country Status (9)

Country Link
EP (1) EP1286591B1 (zh)
JP (1) JP5684964B2 (zh)
CN (3) CN101108176A (zh)
AT (1) ATE483459T1 (zh)
AU (2) AU2000255966B2 (zh)
CA (1) CA2378754A1 (zh)
DE (1) DE60045082D1 (zh)
ES (1) ES2350330T3 (zh)
WO (1) WO2001093683A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101043904B (zh) * 2004-08-24 2012-04-18 N·V·努特里奇亚 含有不可消化寡糖的营养组合物
CN103169660A (zh) * 2013-04-15 2013-06-26 石正国 一种制备高包封率的利巴韦林脂质体口服乳
US9370528B2 (en) 2011-03-02 2016-06-21 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
WO2022003200A1 (en) * 2020-07-03 2022-01-06 pHOxgen Limited Reduction of viral infections

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455776A4 (en) * 2001-12-21 2006-05-17 Bridge Pharma Inc NON-ARYTHMOGENIC METABOLITE OF OXYBUTYNINE
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
CA2836904C (en) 2011-06-03 2019-09-24 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
CA2933204C (en) * 2013-12-18 2020-04-28 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
AU2015269699B2 (en) 2014-06-03 2020-08-13 Avanti Polar Lipids, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
US11806401B2 (en) 2016-04-27 2023-11-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008269A (en) * 1970-05-05 1977-02-15 William H. Rorer, Inc. Phenylacetic acids
IT1231237B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati eterociclici
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101043904B (zh) * 2004-08-24 2012-04-18 N·V·努特里奇亚 含有不可消化寡糖的营养组合物
US9730951B2 (en) 2010-03-03 2017-08-15 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
US10245277B2 (en) 2010-03-03 2019-04-02 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
US9370528B2 (en) 2011-03-02 2016-06-21 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
CN103169660A (zh) * 2013-04-15 2013-06-26 石正国 一种制备高包封率的利巴韦林脂质体口服乳
CN103169660B (zh) * 2013-04-15 2015-04-08 石正国 一种制备高包封率的利巴韦林脂质体口服乳
WO2022003200A1 (en) * 2020-07-03 2022-01-06 pHOxgen Limited Reduction of viral infections

Also Published As

Publication number Publication date
EP1286591A1 (en) 2003-03-05
CA2378754A1 (en) 2001-12-13
CN101108176A (zh) 2008-01-23
AU2000255966B2 (en) 2005-03-24
WO2001093683A1 (en) 2001-12-13
CN1454054A (zh) 2003-11-05
AU5596600A (en) 2001-12-17
AU2000255966A1 (en) 2002-03-07
EP1286591B1 (en) 2010-10-06
JP2003535110A (ja) 2003-11-25
JP5684964B2 (ja) 2015-03-18
ES2350330T3 (es) 2011-01-21
EP1286591A4 (en) 2007-04-04
ATE483459T1 (de) 2010-10-15
DE60045082D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
CN1451388A (zh) 防治病毒引起非典型性肺炎等传染病的药物
TW580392B (en) Process for preparing synthetic soil-extract materials and medicaments based thereon
CN1234346C (zh) 用于气溶胶化的妥布霉素的最佳制剂
CN1120458A (zh) 生理活性肽组合物
EP1970071A1 (en) Use of a topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention
CN1255859A (zh) 含有甘草酸和至少一种具有抗病毒活性的蛋白质的抗病毒药物组合物
CN1197552C (zh) 应用抗炎剂的制剂
CN1927393A (zh) 复合胶原蛋白凝胶
RU2272623C2 (ru) РАСТВОР ТЕТРАГИДРАТА МОНОНАТРИЕВОЙ СОЛИ N-[O-(п-ПИВАЛОИЛОКСИБЕНЗОЛСУЛЬФОНИЛАМИНО)БЕНЗОИЛ]ГЛИЦИНА И ГОТОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА НА ЕГО ОСНОВЕ
KR20200068511A (ko) 지방 분해용 조성물 및 이를 포함하는 주사제 조성물
CN1660116A (zh) 一种新的硫酸头孢匹罗组合物及其制备方法
CN1169115A (zh) 包含皮质甾类的脂质体
CN1843368A (zh) 一种灯盏花素长循环纳米脂质体及其制备方法
CN1111411C (zh) 一种抗菌用的克林霉素磷酸酯粉针剂及其制备方法
CN1806801A (zh) 一种治疗呼吸道感染的新鱼腥草素钠的药物组合物及其制备方法
CN1193790C (zh) 胸腺肽组合物注射剂及其制备方法
CN1290506C (zh) 药物组合物
CN1298327C (zh) 硫酸长春新碱脂质体组合物及其制备方法
CN1616092A (zh) 复合溶菌酶Lysoamidase喷雾剂及制备方法
CN1069192C (zh) 一种气溶胶制剂及其配制方法
JPH03106898A (ja) 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤
CN1272009C (zh) 甘草酸二铵冻干制剂及其制备方法
CN1209320A (zh) 药物
CN1593387A (zh) 包封两亲性药物的脂质体的制备方法及其制剂
CN1063943C (zh) 适合于局部用药的含氨卡霉素的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication